Potential Application of Copper Aspirinate in Preventing and Treating Thromboembolic Diseases
1998
Potential Application of Copper Aspirinate in Preventing and Treating Thromboembolic Diseases
Sample size: 60
publication
Evidence: moderate
Author Information
Author(s): Weiping Liu, Huizhou Xiong, Yikun Yang, Ling Li, Zhiqiang Shen, Zhihe Chen
Primary Institution: Institute of Precious Metals, Kunming Medical College
Hypothesis
Copper aspirinate may be a potential antithrombotic drug.
Conclusion
Copper aspirinate shows promise in preventing and treating thrombotic diseases, particularly cerebral ischemia.
Supporting Evidence
- Copper aspirinate significantly prolonged bleeding time compared to control.
- Copper aspirinate reduced mortality from 87% to 13% in mice.
- Copper aspirinate improved survival rates in gerbils after cerebral ischemia.
- Copper aspirinate decreased brain calcium concentration during ischemia.
- Copper aspirinate increased the density of intact hippocampal CA1 cells.
Takeaway
Copper aspirinate might help prevent blood clots and protect the brain from damage.
Methodology
Animal models were used to test the effects of copper aspirinate on bleeding time, mortality, and cerebral ischemia.
Limitations
The study was conducted on animal models, which may not fully represent human responses.
Participant Demographics
ICR mice and Mongolian gerbils of either sex.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website